Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension

Mitsushige Murata; Takashi Kawakami; Masaharu Kataoka; Takashi Kohno; Yuji Itabashi; Keiichi Fukuda

doi:10.1177/2045893217746111

Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension

Pulm Circ. 2018 Jan-Mar;8(1):2045893217746111. doi: 10.1177/2045893217746111. Epub 2017 Dec 18.

Authors

Mitsushige Murata¹, Takashi Kawakami², Masaharu Kataoka², Takashi Kohno², Yuji Itabashi², Keiichi Fukuda²

Affiliations

¹ 1 Department of Laboratory Medicine, School of Medicine, Keio University, Tokyo, Japan.
² 2 Department of Cardiology, School of Medicine, Keio University, Tokyo, Japan.

Abstract

Riociguat is a soluble guanylate cyclase stimulator used for pulmonary hypertension (PH) treatment. We evaluated right ventricular (RV) contractile function in 27 PH patients receiving riociguat. A comparison of pre- and post-administration echocardiographic studies demonstrated significantly improved RV strain after riociguat treatment, even after adjusting for RV afterload.

Keywords: pulmonary hypertension; right ventricular contraction; riociguat.